Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Maris · SciRah

Researcher profile · Semantic Scholar

M. Maris

Share profile

M. Maris — researcher profile on SciRah

h-index: 48
Works: 185
Citations: 13K

Most-cited papers

Long-Term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
M. Sorror, B. Sandmaier, B. Storer, G. Franke +22 more
2011Journal of the American Medical Association (JAMA)294 citations Open access
Semantic Scholar
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
L. Burroughs, P. O'Donnell, B. Sandmaier, B. Storer +14 more
2008Biology of Blood and Marrow Transplantation272 citations Open access
Semantic Scholar
Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
R. Swords, H. Erba, D. DeAngelo, D. Bixby +9 more
2015British Journal of Haematology225 citations Open access
Semantic Scholar
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
B. Gyurkocza, R. Storb, B. Storer, T. Chauncey +16 more
2010Journal of Clinical Oncology217 citations Open access
Semantic Scholar
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
H. Kantarjian, H. Erba, D. Claxton, M. Arellano +12 more
2010Journal of Clinical Oncology204 citations
Semantic Scholar
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
R. Swords, S. Coutre, M. Maris, J. Zeidner +13 more
2018Blood192 citations Open access
Semantic Scholar
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
S. Faderl, M. Wetzler, D. Rizzieri, G. Schiller +19 more
2012Journal of Clinical Oncology173 citations Open access
Semantic Scholar
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
D. Steensma, M. Wermke, V. Klimek, P. Greenberg +36 more
2021Leukemia172 citations Open access
Semantic Scholar
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
S. Ansell, M. Maris, A. Lesokhin, Robert Chen +22 more
2021Clinical Cancer Research172 citations Open access
Semantic Scholar
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
G. Laport, B. Sandmaier, B. Storer, B. Scott +16 more
2008Biology of Blood and Marrow Transplantation143 citations Open access
Semantic Scholar
Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes
G. Garcia-Manero, G. Montalban-Bravo, J. Berdeja, Yasmin M. Abaza +18 more
2017Cancer109 citations Open access
Semantic Scholar
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia
R. Ram, R. Storb, B. Sandmaier, D. Maloney +9 more
2011Haematologica102 citations Open access
Semantic Scholar
Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.
M. Sorror, P. Martin, R. Storb, S. Bhatia +10 more
2014Blood99 citations Open access
Semantic Scholar
Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
P. Shaughnessy, M. Islas‐Ohlmayer, Julie A. Murphy, Maureen Hougham +8 more
2011Biology of Blood and Marrow Transplantation94 citations Open access
Semantic Scholar
Effectiveness of addition of sirolimus to cyclosporine and mycophenolate mofetil-based graft-versus-host disease prophylaxis after unrelated nonmyeloablative hematopoietic cell transplantation: A multicentre phase III randomized trial
B. Sandmaier, B. Kornblit, B. Storer, G. Olesen +14 more
2019The Lancet Haematology88 citations Open access
Semantic Scholar
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
D. Steensma, M. Wermke, V. Klimek, Peter L. Greenberg +32 more
2019Blood81 citations Open access
Semantic Scholar
Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
H. Nakamae, K. Kirby, B. Sandmaier, L. Norasetthada +6 more
2009Biology of Blood and Marrow Transplantation81 citations Open access
Semantic Scholar
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
A. Raza, J. Jurcic, G. Roboz, M. Maris +7 more
2009Leukemia and Lymphoma65 citations
Semantic Scholar
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
I. Flinn, J. Gribben, M. Dyer, W. Wierda +17 more
2019Blood61 citations Open access
Semantic Scholar
BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study
J. Abramson, K. Blum, I. Flinn, M. Gutierrez +9 more
201555 citations
Semantic Scholar
Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia
Eunice S. Wang, O. Frankfurt, K. Orford, M. Bennett +3 more
201542 citations
Semantic Scholar
A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
K. Blum, J. Abramson, M. Maris, I. Flinn +18 more
201840 citations Open access
Semantic Scholar
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation
B. Kornblit, D. Maloney, B. Storer, M. Maris +13 more
2014Haematologica40 citations Open access
Semantic Scholar
Low-dose Total Body Irradiation and Fludarabine Conditioning for HLA-Class I Mismatched Donor Stem Cell Transplantation and Immunological Recovery in Patients with Hematological Malignancies: A Multi-Center Trial
H. Nakamae, B. Storer, R. Storb, J. Storek +11 more
2009Biology of Blood and Marrow Transplantation39 citations Open access
Semantic Scholar
Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
I. Flinn, M. Cherry, M. Maris, J. Matous +2 more
2019American journal of hematology/oncology35 citations Open access
Semantic Scholar
A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
S. Ansell, Robert Chen, I. Flinn, M. Maris +6 more
201635 citations
Semantic Scholar
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
Jason P. Cooper, B. Storer, Noa Granot, B. Gyurkocza +31 more
2020Haematologica34 citations Open access
Semantic Scholar
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
K. Blum, J. Supko, M. Maris, I. Flinn +9 more
2022Cancer Research Communications33 citations Open access
Semantic Scholar
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
R. Stuart, L. Cripe, M. Maris, Maureen A. Cooper +13 more
2014British Journal of Haematology31 citations Open access
Semantic Scholar
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
J. Lancet, G. Roboz, L. Cripe, G. Michelson +9 more
2015Haematologica28 citations Open access
Semantic Scholar
A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart® Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies
E. Winer, M. Maris, Manish R Sharma, P. Kaminker +3 more
2022Blood25 citations Open access
Semantic Scholar
CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
K. Patel, J. Zonder, Dahlia Sano, M. Maris +11 more
2021Blood25 citations Open access
Semantic Scholar
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)
A. Lane, K. Sweet, Eunice S. Wang, W. Donnellan +17 more
201625 citations
Semantic Scholar
A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
H. Erba, M. Levy, S. Vasu, A. Stein +12 more
201625 citations
Semantic Scholar
Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors.
B. Kornblit, B. Storer, N. Andersen, M. Maris +7 more
2020Blood24 citations Open access
Semantic Scholar
Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
J. Watts, M. Maris, Tara L. Lin, Prapti A. Patel +10 more
2022Blood19 citations Open access
Semantic Scholar
Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
I. Flinn, J. Gribben, M. Dyer, W. Wierda +11 more
201719 citations
Semantic Scholar
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
K. Patel, R. Ramchandren, M. Maris, A. Lesokhin +11 more
202018 citations Open access
Semantic Scholar
Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
S. Horwitz, J. Foran, M. Maris, A. Sawas +21 more
2020Blood17 citations
Semantic Scholar
Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia
I. Flinn, M. Cherry, M. Maris, J. Matous +2 more
201516 citations
Semantic Scholar
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy
Fevzi F. Yalniz, J. Berdeja, M. Maris, R. Lyons +7 more
2020British Journal of Haematology15 citations
Semantic Scholar
H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies.
D. Steensma, M. Maris, Jay Yang, W. Donnellan +15 more
201715 citations
Semantic Scholar
A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).
T. Kovacsovics, M. Levy, R. Cook, J. Kolitz +13 more
2019Journal of Clinical Oncology14 citations
Semantic Scholar
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
M. Shadman, D. Maloney, B. Storer, B. Sandmaier +14 more
2019Bone Marrow Transplantation12 citations Open access
Semantic Scholar
An Open-Label, Phase Ib Study of Duvelisib (IPI-145) in Combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with Lymphoma or Chronic Lymphocytic Leukemia
I. Flinn, M. Patel, M. Maris, J. Matous +2 more
201412 citations
Semantic Scholar
ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
M. Davids, S. Kenderian, I. Flinn, B. Hill +11 more
2022Blood11 citations Open access
Semantic Scholar
Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)
R. Swords, S. Coutre, M. Maris, J. Zeidner +12 more
201611 citations
Semantic Scholar
Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial
R. Swords, M. Savona, M. Maris, H. Erba +8 more
201411 citations
Semantic Scholar
Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.
R. Stuart, F. R. Kashani, L. Cripe, M. Maris +6 more
201011 citations
Semantic Scholar
TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
S. Ansell, I. Flinn, M. Maris, O. O'Connor +11 more
201710 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

I. Flinn×15
Invite
I. Flinn — researcher profile on SciRah
B. Sandmaier×13
Invite
B. Sandmaier — researcher profile on SciRah
D. Maloney×13
Invite
D. Maloney — researcher profile on SciRah
R. Storb×12
Invite
R. Storb — researcher profile on SciRah

×11

Invite

B. Storer — researcher profile on SciRah

T. Chauncey×10

Invite

T. Chauncey — researcher profile on SciRah

M. Pulsipher×8

Invite

M. Pulsipher — researcher profile on SciRah

Invite

J. Berdeja — researcher profile on SciRah

Invite

A. Langston — researcher profile on SciRah

Invite

B. Bruno — researcher profile on SciRah

Invite

R. Maziarz — researcher profile on SciRah

Invite

W. Bethge — researcher profile on SciRah